| scholarly article | Q13442814 |
| P2093 | author name string | Narsing A Rao | |
| Gary N Holland | |||
| Douglas A Jabs | |||
| John Kempen | |||
| Richard J Stawell | |||
| Oren Tomkins-Netzer | |||
| Susan Lightman | |||
| Albert Vitale | |||
| Lea Drye | |||
| Multicenter Uveitis Steroid Treatment Trial Research Group | |||
| P2860 | cites work | Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop | Q24727581 |
| Pars planitis: clinical features and class II HLA associations | Q33541979 | ||
| Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy | Q33765919 | ||
| Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. | Q33920749 | ||
| The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics | Q34286402 | ||
| Birdshot retinochoroidopathy: ocular complications and visual impairment | Q34436152 | ||
| Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity | Q34568349 | ||
| Loss of visual field among patients with birdshot chorioretinopathy | Q34712728 | ||
| Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema | Q35065882 | ||
| Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial | Q35319079 | ||
| Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography | Q35570770 | ||
| The impact of macular edema on visual function in intermediate, posterior, and panuveitis. | Q36814725 | ||
| Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial | Q37038644 | ||
| Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema | Q37135393 | ||
| Optical coherence tomography evaluation in the Multicenter Uveitis Steroid Treatment (MUST) trial | Q37299519 | ||
| Causes and frequency of blindness in patients with intraocular inflammatory disease | Q37319691 | ||
| The natural history of uveitis | Q38002324 | ||
| Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results | Q38387242 | ||
| Macular thickening and visual acuity. Measurement in patients with cystoid macular edema | Q41466372 | ||
| Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study | Q41576239 | ||
| Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema | Q44676246 | ||
| Tomographic assessment of therapeutic response to uveitic macular oedema | Q46903671 | ||
| Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum | Q71074360 | ||
| Pars planitis: a 20-year study of incidence, clinical features, and outcomes | Q79956707 | ||
| Course of macular edema in uveitis under medical treatment | Q80454666 | ||
| Long-term clinical outcome and causes of vision loss in patients with uveitis | Q85230964 | ||
| P433 | issue | 11 | |
| P921 | main subject | uveitis | Q280027 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 2351-2359 | |
| P577 | publication date | 2015-09-07 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results | |
| P478 | volume | 122 |
| Q89134217 | Comment on: "Autoimmune uveitis: clinical, pathogenetic, and therapeutic features" |
| Q24186144 | Corticosteroid implants for chronic non-infectious uveitis |
| Q38956279 | Doyne lecture 2016: intraocular health and the many faces of inflammation |
| Q98613396 | Drug Tissue Distribution of TUDCA From a Biodegradable Suprachoroidal Implant versus Intravitreal or Systemic Delivery in the Pig Model |
| Q47932596 | Immunosuppression for the Uveitides |
| Q98467232 | Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis |
| Q58806282 | Intravitreal therapeutic agents in noninfectious uveitic macular edema |
| Q92294549 | KS23, a novel peptide derived from adiponectin, inhibits retinal inflammation and downregulates the proportions of Th1 and Th17 cells during experimental autoimmune uveitis |
| Q41989664 | Ocular Autoimmune Systemic Inflammatory Infectious Study - Report 3: Posterior and Panuveitis |
| Q57072240 | Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial |
| Q91588401 | Perioperative Management of Uveitic Cataracts |
| Q61810687 | Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis |
| Q49965944 | RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE. |
| Q60303850 | Spectral domain optical coherence tomography as an adjunctive tool for screening Behçet uveitis |
| Q64226421 | Update in treatment of uveitic macular edema |
Search more.